Monitor the ESMO abstract release on October 19, 2026, and the presentation on October 23 for the actual data readout. The stock may see volatility around those dates depending on efficacy and safety results. No immediate trading catalyst from this announcement alone.
Price Chart
Executive Summary
Perspective Therapeutics announced that updated data from its [212Pb]VMT-α-NET program for neuroendocrine tumors has been accepted for a rapid oral presentation at the ESMO Congress 2026 in October. This is a positive clinical milestone for a radiopharmaceutical development company, but no new data or financial figures were released in this press release, making it a routine pipeline update with limited immediate trading impact.
Key Facts
- Updated data on the [212Pb]VMT-α-NET program accepted for rapid oral presentation at ESMO Congress 2026 (Oct 23-27, Madrid).
- Presentation covers cohort-level safety and efficacy results for Cohorts 1-3 in advanced SSTR2+ neuroendocrine tumors.
- Abstract number 2396RO; presentation date October 23, 2026.
- No new clinical data or financial results were disclosed in this press release.
Financial Impact
No financial figures disclosed in the press release.
Risk Factors
- Clinical data may fail to show sufficient efficacy or safety, leading to stock decline.
- Competition from other radiopharmaceutical and targeted therapies for NETs.
- Company is pre-revenue and relies on capital markets for funding; cash burn risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3329221 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers